RxDoctor Payments Data

Nirav Patel, DO

Pain Medicine · New Albany, INNPI 1588042600

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Saluda Medical Americas, Inc. at 34.5% of the total. Reporting peaked in 2024 at $3,205 and has fallen 87.7% since, to $393 in 2025.

$6,531in general payments, 2019–2025

Across 84 payments — averaging $77.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$2K
  • Boston Scientific$2K
  • Medtronic$947
  • Stryker$555
  • Nevro Corp.$249
  • Abbott$119
  • plus $323 from 13 others

What the payments were for

  • Travel & lodging$3,62556%
  • Food & beverage$2,77342%
  • Education$1332%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,531 in reported general payments places this provider in the 70th percentile of 128 pain medicine providers in Indiana.

See all pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$134,036
Medicare patients
240
Services billed
2,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide23$19,880
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen713$13,162
NucyntaTapentadol Hcl11$9,945
Pregabalin253$8,175
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen311$6,518
MovantikNaloxegol Oxalate11$6,095
Gabapentin327$4,304
Celecoxib37$2,735
Lidocaine14$1,101
Oxycodone Hcl58$1,051
Morphine Sulfate ErMorphine Sulfate34$836
Tizanidine Hcl108$683
Tramadol Hcl101$639
Meloxicam53$582
Cyclobenzaprine Hcl97$546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$22$19,88023 claims
Hikma Pharmaceuticals USAMorphine Sulfate, Buprenorphine Hcl$14$54535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 128 pain medicine providers in Indiana.

Other pain medicine in New Albany

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →